F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome - PubMed (original) (raw)
F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome
Serena Masciari et al. JAMA. 2008.
Abstract
Context: Individuals with Li-Fraumeni syndrome (LFS) have an inherited cancer predisposition to a diverse array of malignancies beginning early in life; survivors of one cancer have a markedly elevated risk of additional primary tumors. The underlying genetic defect in the majority of the families is a germline mutation in the TP53 tumor suppressor gene. The diversity of tumors and rarity of families have contributed to the difficulty in devising effective screening recommendations for members of LFS kindreds.
Objective: To gather preliminary data with which to evaluate F18-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) imaging as a potential surveillance modality to detect early malignancies in asymptomatic members of LFS kindreds.
Design, setting, and participants: Members of LFS families with documented germline TP53 mutations or obligate carrier status, no history of cancer within 5 years of enrollment, and no symptoms of cancer or ill-health were offered FDG-PET/CT scanning as a screening test in a comprehensive US cancer center from 2006 to 2007. Scans were initially reviewed clinically, then centrally reviewed by an expert radiologist.
Main outcome measure: The primary outcome was the detection of new primary cancers using FDG-PET/CT scanning.
Results: Of 15 individuals, baseline FDG-PET/CT scan identified asymptomatic cancers in 3 (20%). Two individuals had papillary thyroid cancers (stage II and stage III) and one individual had stage II esophageal adenocarcinoma.
Conclusions: These preliminary data provide the first evidence for a potential cancer surveillance strategy that may be worthy of further investigation for patients with LFS. Concerns about radiation exposure and other challenges inherent in screening high-risk patients will require further consideration.
Similar articles
- TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van 't Veer LJ. Ruijs MW, et al. J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429. J Med Genet. 2010. PMID: 20522432 - [Li-Fraumeni syndrome: update, new data and guidelines for clinical management].
Frebourg T, Abel A, Bonaiti-Pellie C, Brugières L, Berthet P, Bressac-de Paillerets B, Chevrier A, Chompret A, Cohen-Haguenauer O, Delattre O, Feingold J, Feunteun J, Frappaz D, Fricker JP, Gesta P, Jonveaux P, Kalifa C, Lasset C, Leheup B, Limacher JM, Longy M, Nogues C, Oppenheim D, Sommelet D, Soubrier F, Stoll C, Stoppa-Lyonnet D, Tristant H. Frebourg T, et al. Bull Cancer. 2001 Jun;88(6):581-7. Bull Cancer. 2001. PMID: 11459705 Review. French. - Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J, Selistre SG, Rossi C, Alemar B, Santos-Silva P, Pereira FS, Netto CB, Cossio SL, Roth DE, Brunetto AL, Zagonel-Oliveira M, Martel-Planche G, Goldim JR, Hainaut P, Camey SA, Ashton-Prolla P. Giacomazzi J, et al. Cancer. 2013 Dec 15;119(24):4341-9. doi: 10.1002/cncr.28346. Epub 2013 Oct 7. Cancer. 2013. PMID: 24122735 - Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC. Bojadzieva J, et al. Fam Cancer. 2018 Apr;17(2):287-294. doi: 10.1007/s10689-017-0034-6. Fam Cancer. 2018. PMID: 28988289 - [Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI].
Foretová L, Stěrba J, Opletal P, Mach V, Lisý J, Petráková K, Palácová M, Navrátilová M, Gaillyová R, Puchmajerová A, Křepelová A, Macháčková E. Foretová L, et al. Klin Onkol. 2012;25 Suppl:S49-54. Klin Onkol. 2012. PMID: 22920207 Review. Czech.
Cited by
- Childhood predictive genetic testing for Li-Fraumeni syndrome.
Evans DG, Lunt P, Clancy T, Eeles R. Evans DG, et al. Fam Cancer. 2010 Mar;9(1):65-9. doi: 10.1007/s10689-009-9245-9. Epub 2009 Apr 30. Fam Cancer. 2010. PMID: 19404774 - "Metabolic signature" of the lesions on F18-fluoro-deoxyglucose positron emission tomography: A clue to the underlying pathology.
Kashyap R, Chakravarthy R, Reddy K, Ali MA, Buddharaju LN, Muntimadugu B. Kashyap R, et al. Indian J Nucl Med. 2014 Jul;29(3):193-4. doi: 10.4103/0972-3919.136601. Indian J Nucl Med. 2014. PMID: 25210294 Free PMC article. - Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
Formiga MNDC, de Andrade KC, Kowalski LP, Achatz MI. Formiga MNDC, et al. JAMA Oncol. 2017 Oct 1;3(10):1400-1402. doi: 10.1001/jamaoncol.2016.6389. JAMA Oncol. 2017. PMID: 28114597 Free PMC article. - Radiation-sensitive genetically susceptible pediatric sub-populations.
Kleinerman RA. Kleinerman RA. Pediatr Radiol. 2009 Feb;39 Suppl 1(Suppl 1):S27-31. doi: 10.1007/s00247-008-1015-6. Epub 2008 Dec 16. Pediatr Radiol. 2009. PMID: 19083227 Free PMC article. Review. - HABP2 p.G534E variant in patients with family history of thyroid and breast cancer.
Pinheiro M, Drigo SA, Tonhosolo R, Andrade SCS, Marchi FA, Jurisica I, Kowalski LP, Achatz MI, Rogatto SR. Pinheiro M, et al. Oncotarget. 2017 Jun 20;8(25):40896-40905. doi: 10.18632/oncotarget.16639. Oncotarget. 2017. PMID: 28402931 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous